All In Biotech

Drug Trial Radar · NCT05087069

Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Healthy Male Subjects

A Phase I, Single-centre, Double-blind, Randomised, Placebo-controlled Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 Administered as Multiple Intravenous Doses to Healthy Male Subjects

Last checked: Nov 19, 2026Latest source record: Jan 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Oct 8, 2021

Primary completion

Apr 8, 2022

Study completion Jan 12, 2023

Sponsor

Lead sponsor
BioVersys SASIndustry
Sponsor type
Industry
Collaborators
Nuvisan GmbH
First posted
Oct 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Safety and tolerability and Pharmacokinetics of multiple doses of BV100 in healthy volunteers

Conditions

  • Healthy Volunteers

Interventions

  • BV100Drug

    Rifabutin for Infusion

  • PlaceboDrug

    Saline intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To investigate the safety and tolerability of increasing multiple intravenous doses of BV100Time frame: 21 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nuvisan GmbH

    Neu-Ulm, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.